ColdSteel Laser, Inc. Wins “Best in Show” at 1st Pitch Life Science Competition


ColdSteel Laser, Inc. Wins “Best in Show” at 1st Pitch Life Science Competition

October 24, 2017 09:45 ET | Source: Mid Atlantic Bio Angels

 

NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) — Mid-Atlantic Bio Angels (MABA) announces today that ColdSteel Laser, Inc. (http://www.coldsteellaser.com), which is developing an endoscopic image guided robotic laser scalpel, was named “Best in Show” by the audience and “Most Fundable” by the investor panel at MABA’s 1st Pitch Life Science event held on October 16, 2017 at NYU Langone Medical Center in New York City.

“We are honored to be chosen as winner of both ‘Best in Show’ and ‘Most Fundable,’” said Jerry Korten, CEO of ColdSteel Laser, Inc. “We are dedicated to improving surgical procedures to minimize errors using our proprietary technology to ensure accuracy. It is gratifying to be recognized for our work, and we hope to utilize the feedback we received to refine our business plan.”

Brooklyn-based ColdSteel Laser, Inc. is developing proprietary, endoscopic robotic laser scalpel technology for use in ear/nose/throat, gynecological and other surgical procedures where extremely precise tissue incision is critical. Their innovation will allow the use of a laser for image guided precision targeting and restore the surgeon’s ability to use two hands for endoscopic tissue manipulation to minimize collateral damage.

“Cold Steel Laser has improved the art of delicate surgical procedures with their user-friendly, lower-risk surgical device,” said Craig Kenesky, Ph.D. of Wilson Sonsini Goodrich & Rosati, PC, a panelist at the event.

“While there is always risk at this stage, Cold Steel’s technology, the management and the plan seem promising. The presentation offered a cogent case for investment,” added Stephen Goodman, co-founder of MABA and partner at Pryor Cashman, LLP in New York City.

About 1st Pitch Life Science
At a 1stPitch event (http://www.1stpitchlifescience.com), early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1stPitch are invited to hear the panel constructively critique the company’s presentation, business model and perceived viability in the market.

About MABA
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA’s goal is to create an environment where the depth of investors’ knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.

 

Leave a comment

Your email address will not be published. Required fields are marked *